References and Recommended Reading
Mayeux R:Epidemiology of neurodegeneration.Ann Rev Neurosci 2003, 26:81–104.
de Lau LM:Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study.Neurology 2004, 63:1240–1244.
Of importance Rao J:Neurochemistry of nigral degeneration. InHandbook of Parkinson’s Disease. Edited by Pahwa R, Lyons KE. New York: Futura; 2007: In press. A review of molecular mechanisms that may make the ventral tier of dopaminergic neurons of substantia nigra pars compacta more vulnerable to degeneration than the ventral tegmental area dopaminergic neurons.
Of major importance Rao J:Neurochemistry of Parkinson’s disease. InParkinson’s Disease and Related Disorders. Handbook of Clinical Neurology Series. Edited by Koller WC, Malamed E. New York: Elsevier; 2007: In Press. A detailed discussion of neurochemical changes in dopaminergic and nondopaminergic systems in PD.
Rascol O:A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group.N Engl J Med 2000, 342:1484–1491.
Rascol O:Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.Mov Disord 2006, 21:1844–1850.
Ahlskog JE:Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature.Mov Disord 2001, 16:448–458.
Linazasoro G:New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.Trends Pharmacol Sci 2005, 26:391–397.
Of major importance Jankovic J:Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations.Mov Disord 2005, 20(Suppl 11):S11-S16. A comprehensive review of clinical features of motor fluctuations in PD.
Pechevis M:Effects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European study.Eur J Neurol 2005, 12:956–963.
Of major importance Samadi P:Opioids and motor complications in Parkinson’s disease.Trends Pharmacol Sci 2006, 27:512–517. An excellent analysis of the role played by opioids in dyskinesia in animal models of PD.
Cenci MA:L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.Eur J Neurosci 1998, 10:2694–2706.
Johansson PA:Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of 1-DOPA-induced dyskinesia.Neurobiol Dis 2001, 8:220–239.
Hallett PJ:Rationale for and use of NMDA receptor antagonists in Parkinson’s disease.Pharmacol Ther 2004, 102:155–174.
Of major importance Chen HS:The chemical biology of clnically tolerated NMDA receptor antagonists.J Neurochem 2006, 97:1611–1626. Excellent review of the mechanisms of actions of NMDA antagonists, especially that of memantine.
Nicholson SL:5-hydroxytryptamine (5-HT, serotonin) and Parkinson’s disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy.Eur J Neurol 2002, 9(Suppl 3):1–6.
Of importance Brotchie JM:Nondopaminergic mechanisms in levodopa-induced dyskinesia.Mov Disord 2005, 20:919–931. A good review of the nondopaminergic mechanisms underlying levodopa-induced dyskinesia.
Colosimo C:Noradrenergic drugs for levodopa-induced dyskinesia.Clin Neuropharmacol 2003, 26:299–305.
Of major importance Metman LV:Role of surgery in the treatment of motor complications.Mov Disord 2005, 20(Suppl 11):S45-S56. An excellent review of the role of DBS surgery in motor complications.
Fraix V:Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson’s disease. 2000.Neurology 2001, 57:S60-S62.
Metman LV:Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.Arch Neurol 1999, 56:1383–1386.
Reis J:Modulation of human motor cortex excitability by single doses of amantadine.Neuropsychopharmacology 2006, 31:2758–2766.
Kornhuber J:Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study.Eur J Pharmacol 1991, 206:297–300.
Kornhuber J:Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex.Neurosci Lett 1993, 163:129–131.
Rajput AH:Amantadine ameliorates levodopa induced dyskinesia.Neurology 1997, 48:A328.
Of major importance Nutt JG:Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa? Mov Disord 2007, 22:1–9. A careful analysis of the validity of the “continuous dopaminergic stimulation” concept.
Katzenschlager R:Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges.Mov Disord 2005, 20:151–157.
Of major importance Zanettini R:Valvular heart disease and the use of dopamine agonists for Parkinson’s disease.N Engl J Med 2007, 356:39–46. The link between ergot-derived dopamine agonists and their causal relationship with cardiac valvular disease is reinforced with additional cases.
Durif F:Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.Neurology 2004, 62:381–388.
Of major importance Dean B, Scarr E:Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.Curr Drug Targets CNS Neurol Disord 2004, 3:217–225. A good synposis of the mechanisms of action of atypical antipsychotics.
Baron MS:Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson’s disease.Mov Disord 2003, 18:1208–1209.
Katzenschlager R, Manson AJ, Evans A, et al.:Low dose quetiapine for drug induced dyskinesias in Parkinson’s disease: a double blind cross over study.J Neurol Neurosurg Psychiatry 2004, 75:295–297.
Of major importance Pahwa R:Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology 2006, 66:983–995. An evidence-based review of medical and surgical treatment of dyskinesia and motor fluctuations.
Of major importance Fraix V:Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson’s disease.J Neurol Neurosurg Psychiatry 2006, 77:443–449. A good discussion of economic consequences of DBS in PD.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rao, J. Treatment of levodopa-induced dyskinesia. Curr Treat Options Neurol 9, 205–209 (2007). https://doi.org/10.1007/BF02938410
Issue Date:
DOI: https://doi.org/10.1007/BF02938410